Oral cancers are the cancers of the mouth and the pharynx. Symptoms include red patch in the mouth, difficulty chewing, Hoarseness, soreness. Oral cancers are mostly reported in adults. They are life threatening if not diagnosed and treated early. Most cases of oral cancer are a result of cigarette smoking and heavy alcohol. The top journals are peer reviewed scholarly journals. These provide high quality, meticulously reviewed and rapid publication, to cater the insistent need of scientific community. These journals are indexed with all their citations noted. The top open access journals are indexed in MEDLINE, PUBMED, SCOPUS, COPERNICUS, CAS, EBSCO and ISI R.L.F. reports consultancy role for AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, Merck, and Pfizer; grants from AstraZeneca, Bristol-Myers Squibb, and VentiRx. G.B.Jr. reports grants from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Immatics, Macrogenics, Merck, Novartis, and Xcovery; consultancy fees from ARIAD, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Genentech, Immatics, Merck, Novartis, and Xcovery; advisory board participation for Bayer. J.F. reports personal fees from AstraZeneca and Bristol-Myers Squibb. J.G. reports consultancy role for AstraZeneca, Bristol-Myers Squibb, Innate Pharma, and Merck Serono; grants from Bristol-Myers Squibb, GlaxoSmithKline, and Merck Serono. L.Licitra reports grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck Serono, Merck Sharpe & Dohme, Novartis, and Roche; personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm, Eisai, Merck Serono, Merck Sharpe & Dohme, Novartis, and Roche; travel arrangements from Bayer, Debiopharm, Merck Serono, and Sobi. K.J.H. reports honoraria from AstraZeneca, Bristol-Myers Squibb, Merck, Merck Sharpe & Dohme, and Pfizer; grants from AstraZeneca and Merck Sharpe & Dohme. S.K. reports honoraria and grants from Bristol-Myers Squibb and Roche/Genentech. E.E.V. reports personal fees from AbbVie, Amgen, ARIAD, AstraZeneca, Bayer, Biolumia, and Bristol-Myers Squibb. F.W. reports advisory board fees from Fusion and Merck; grants from Bayer, Bristol-Myers Squibb, Eisai, and Merck. N.F.S. reports advisory board fees from Bristol-Myers Squibb, Eli Lilly, Genentech, Kura Oncology, and Merck. L.C.I.D. reports personal fees from Bristol-Myers Squibb, Merck KGaA, and Merck Sharp & Dohme. R.H. reports personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Merck, and Pfizer. T.R. reports advisory board fees from Bristol-Myers Squibb and Merck KGaA. N.K. reports honoraria from Bayer, Bristol-Myers Squibb, Eisai, Merck Serono, and ONO Pharmaceuticals; grants from AstraZeneca, Pfizer, and ONO Pharmaceuticals. M.T. reports advisory board fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Merck Sharpe & Dohme, ONO Pharmaceuticals, and Pfizer; honoraria from Bayer, Bristol-Myers Squibb, Eisai, and Otsuka; grants from AstraZeneca, Boehringer Ingelheim, Eisai, Merck Sharpe & Dohme, NanoCarrier, Novartis, ONO Pharmaceuticals, and Pfizer. M.L., L.Li, and V.J. are employees of Bristol-Myers Squibb. M.L.G. reports consultancy role for Amgen, AstraZeneca, Aspyrian Therapeutics, Bristol-Myers Squibb, Celgene, and Merck. A.D.C. and C.E. report no conflicts of interest.The work was supported by Bristol-Myers Squibb .The authors thank the patients and their families, as well as the participating teams, for making this study possible. This study was sponsored by Bristol-Myers Squibb ( Princeton , NJ) and ONO Pharmaceutical Company, Ltd. (Osaka, Japan). Writing and editorial assistance was provided by Qiong Wang, PhD, and Beth Burke, PhD, CMPP, of Evidence Scientific Solutions Inc, funded by Bristol-Myers Squibb